Influences of haemodialysis on the binding sites of human serum albumin: Possibility of an efficacious administration plan using binding inhibition

Nephrology Dialysis Transplantation

Volumn 23, Issue 7, 2008, Pages 2304-2310

  Nishio, Toyotaka ^a,b   Takamura, Norito ^c   Nishii, Ryuuichi ^d   Tokunaga, Jin ^c   Yoshimoto, Mitsuyoshi ^a   Kawai, Keiichi ^a,e  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b 1170 1 Shimowada   (Japan)

^c KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d Shiga Medical Center   (Japan)

^e UNIVERSITY OF FUKUI   (Japan)

Author keywords

Binding site; Free fatty acid; Haemodialysis; Human serum albumin; Protein binding

Indexed keywords

3 CARBOXY 4 METHYL 5 PROPYL 2 FURANPROPIONATE; BUCOLOME; CARBON 14; DIAZEPAM; FATTY ACID; FURAN DERIVATIVE; FUROSEMIDE; HIPPURIC ACID; HUMAN SERUM ALBUMIN; INDICAN; UREMIC TOXIN; WARFARIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOANALYZER; BINDING ASSAY; BINDING SITE; CALCULATION; CLINICAL ARTICLE; COMPETITIVE INHIBITION; DRUG PROTEIN BINDING; EVALUATION; FATTY ACID BLOOD LEVEL; FEMALE; FREE FRACTION; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; LIQUID SCINTILLATION COUNTING; MALE; MEASUREMENT; PARAMETER; PRIORITY JOURNAL; PROTEIN BINDING; RADIOACTIVITY; TECHNIQUE; ULTRAFILTRATION;

ADULT; AGED; BARBITURATES; BINDING SITES; CARBON RADIOISOTOPES; DIAZEPAM; DIURETICS; FATTY ACIDS, NONESTERIFIED; FEMALE; FURANS; FUROSEMIDE; HIPPURATES; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPIONIC ACIDS; PROTEIN BINDING; RENAL DIALYSIS; SERUM ALBUMIN; TREATMENT OUTCOME; WARFARIN;

EID: 46849105046     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn002     Document Type: Article

References (23)

1. Sjöholm I, Ekman B, Kober A et al. Binding of drugs to human serum albumin: C. Mol Pharmacol 1979; 16: 767-777
2. Rane A, Villeneuve JP, Stone WJ et al. Plasma binding and disposition of furosemide in the nephritic syndrome and in uremia. Clin Phramacol Ther 1978; 24: 199-207
3. Kragh-Hansen U. Relations between high-affinity binding sites of markers for binding regions on human serum albumin. Biochem J 1985; 225: 629-638
4. Kragh-Hansen U, Chuang V. T. G, Otagiri M. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002; 25: 695-704
5. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005; 20: 309-323
6. Takamura N, Maruyama T, Chosa E et al. Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephritic syndrome. Drug Metab Dispos 2005; 33: 596-602
7. Takamura N, Haruta A, Kodama H et al. Mode of interaction of loop diuretics with human serum albumin and characterization of binding site. Pharm Res 1996; 37: 498-501
8. Sakai T, Maruyama T, Imamura H et al. Mechanism of stereoselective serum binding of ketoprofen after hemodialysis. J Pharmacol Exp Ther 1996; 278: 786-792
9. Takamura N, Maruyama T, Otagiri M. Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia. Clin Chem 1997; 43: 2274-2280
10. Kawai K, Takamura N, Nishii R et al. Competitive displacement of serum protein binding to regulate pharmacokinetics. Proceedings of International Symposium on Serum Albumin and α1-Acid Glycoprotein from Basic Sciences to Clinical Applications (Kumamoto, Japan), 2000, 181-192
11. Sakai T, Yamasaki K, Sako T et al. Interaction mechanism between indoxyl sulphate, a typical uremic toxin bound to site I, and ligands bound to site I of human serum albumin. Pharm Res 2001; 18: 520-524
12. Arimori K, Nakano M, Otagiri M et al. Effects of penicillins on binding of phenytoin to plasma proteins in vitro and in vivo. Biopharm Drug Dispos 1984; 5: 219-227
13. Putnam FW. In Putnam, FW (ed). The Plasma Proteins. New York: Academic Press, 1975, 133-161
14. Wilting J, Van Der Giesen WF, Janssen LHM et al.The effect of albumin conformation on the binding of warfarin to human serum albumin. J Biol Chem 1980; 255: 3032-3037
15. Lesaffer G, Smet R, Lameire N et al. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57
16. Sakai T, Takadate A, Otagiri M. Characterization of binding site of uremic toxins on human serum albumin. Biol Phram Bull 1995; 18: 1755-1761
17. Fraser JR, Lovell RR, Nestel PJ. The production of lipolytic activity in the human forearmin response to heparin. Clin Sci 1961; 20: 351-356
18. Naranjo CA, Sellers EM. Fatty acids modulation of drug binding to plasma protein. In: Reidenberg MM and Erill S (eds). Drug-Protein Binding. New York: Praeger Scientific, 1986, 233-251
19. Smet RD, Kaer JV, Liebich H et al. Heparin-induced release of protein-bound solutes during hemodialysis is an in vitro artifact. Clin Chem 2001; 47: 901-909
20. Wanwimolruk S, Birkett DJ, Brooks PM. Structural requirements for drug binding to site I on human serumalbumin. Mol Pharmacol 1983; 24: 458-463
21. Richieri VG, Anel A, Kleinfeld AM. Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 1993; 32: 7574-7580
22. Kragh-Hansen U. Octanoate binding to the indole- and benzodiazepine- binding region of human serum albmin. Biochem J 1991; 273: 641-644
23. Spector AA, John K, Fletcher JE. Binding of long-chain fatty acids to bovine serum albumin. J Lipid Res 1969; 10: 56-67